Primary-source record
This quarterly update restates that the NDA for aroxybutynin/atomoxetine (AD109, proposed name Oxnimbi) for OSA is under FDA review with a PDUFA goal date of February 28, 2027. The company continues commercial readiness activities ahead of a potential launch.
EX-99.1 2 apmd-ex99_1.htm EX-99.1 EX-99.1 EX-99.1 Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update • New Drug Application (“NDA”) for AD109, with a proposed proprietary name Oxnimbi™ (aroxybutynin and atomoxetine) tablets, for oral use, remains under U.S. Food and Drug Administration (“FDA”) review with a February 28, 2027, Prescription Drug User Fee Act (“PDUFA”) goal date • Commercial readiness activities advance in preparation for a potential U.S. launch • Presented five abstracts at CHEST 2026, including two late-breakers, highlighting AD109 Phase 3 clinical data and the burden of OSA • $351.8 million in cash and cash equivalents as of September 30, 2026, expected to fund the potential U.S. launch of Oxnimbi and operations into the second quarter of 2028 CAMBRIDGE, Mass., November 16, 2026 – Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update. “We are in a transformational period at Apnimed,” said Kevin Lind, Chief Executive Officer of Apnimed. “With our NDA for AD109 (proposed proprietary name Oxnimbi) under FDA review and a PDUFA goal date of February 28, 2027, we are advancing our launch readiness while continuing to strengthen t